Divi's Laboratories Limited
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients
What Divi's files
- Others54
- Investor Meet24
- Board Meeting9
- Important9
- Dividend/Bonus4
- Results1
Divi's Laboratories has announced a board meeting where it approved the financial results for the quarter ended June 30, 2026. Consolidated PAT climbed to ₹902 Cr from ₹545 Cr year-on-year. The board also appointed Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel.
Divi's Labs approved robust Q4 and FY26 consolidated results: PAT hit ₹751 Cr for Q4 and ₹2568 Cr for the full year. The Board also declared a ₹30/share dividend (1500%) for FY26, pending shareholder approval at the AGM on Aug 10.
Divi's Labs' board approved consolidated financial results for Q4 & FY26. Total income hit ₹2986 Cr (Q4) & ₹11067 Cr (FY26). PAT stood at ₹751 Cr (Q4) & ₹2568 Cr (FY26). The board also proposed a final dividend of ₹30/share for FY26.
Divi's Lab's board approved consolidated financial results for the quarter and nine months ended Dec 31, 2025. Q3 Total Income stood at ₹2692 Cr, with PAT at ₹583 Cr. An exceptional ₹74 Cr charge from new labor codes affected PBT.
Divi's Labs' board approved Q2 consolidated results: Total Income ₹2860 Cr, PAT ₹689 Cr. Half-year consolidated results: Total Income ₹5389 Cr, PAT ₹1234 Cr. Strong forex gains also noted. Mr. N.V. Anirudh is now President (Nutraceuticals), heading the division.